{"preliminary_commentary":{"by_channel":{"x_thread":10,"youtube":1,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04628494\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["epcoritamab"]],"indication":"relapsed/refractory diffuse large B-cell lymphoma","name":"EPCORE DLBCL-1","nct_id":"NCT04628494","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=epcore-dlbcl-1-nct04628494. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"EPCORE DLBCL-1","arms":[{"description":"Epcoritamab will be administered in Cycles of 28 days until any of the discontinuation criteria is met","label":"Epcoritamab (GEN3013; DuoBody®CD3xCD20)","type":"EXPERIMENTAL"},{"description":"R-GemOx will be administrated in Cycles of 28 days until maximum cycles completion or any of the discontinuation criteria is met\n\nBR will be administrated in Cycles of 21 days until maximum cycles completion or any of the discontinuation criteria is met","label":"Investigator's choice of chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":["AbbVie"],"completion_date":{"date":"2028-04","type":"ESTIMATED"},"conditions":["Diffuse Large B-cell Lymphoma"],"enrollment":{"count":483,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Epcoritamab","otherNames":["GEN3013","DuoBody®-CD3xCD20","EPKINLY™"],"type":"BIOLOGICAL"},{"name":"Investigator's Choice Chemotherapy","otherNames":["BR or R-GemOx"],"type":"DRUG"}],"last_update":"2026-05-22","lead_sponsor":"Genmab","official_title":"A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-10-13","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 5 years"}],"references":[],"start_date":{"date":"2021-01-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)","url":"https://clinicaltrials.gov/study/NCT04628494"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/epcore-dlbcl-1-nct04628494"}